Search Results for "Alopecia"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Alopecia. Results 81 to 90 of 97 total matches.
Elafibranor (Iqirvo) for Primary Biliary Cholangitis
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024 (Issue 1718)
pain, alopecia, 151.50
Urso Forte (Allergan) 500 mg scored tabs divided doses diarrhea, nausea ...
Elafibranor (Iqirvo – Ipsen), a peroxisome proliferator-activated
receptor (PPAR) agonist, has been granted
accelerated approval by the FDA for treatment of
primary biliary cholangitis (PBC) in adults. It is
indicated for use in combination with ursodeoxycholic
acid (ursodiol, UDCA; Urso, and others) in patients
with an inadequate response to UDCA alone and as
monotherapy in those unable to tolerate UDCA.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):202-4 doi:10.58347/tml.2024.1718b | Show Introduction Hide Introduction
Seladelpar (Livdelzi) for Primary Biliary Cholangitis
The Medical Letter on Drugs and Therapeutics • Jan 20, 2025 (Issue 1720)
pain, alopecia, diarrhea, 151.50
Urso Forte (Allergan) 500 mg scored tabs 2-4 divided doses nausea ...
Seladelpar (Livdelzi – Gilead), a peroxisome
proliferator-activated receptor (PPAR)-delta agonist,
has received accelerated approval from the FDA for use
in combination with ursodeoxycholic acid (ursodiol,
UDCA; Urso Forte, and generics) for treatment of
primary biliary cholangitis (PBC) in adults who had an
inadequate response to UDCA and as monotherapy in
those unable to tolerate UDCA. Accelerated approval
was based on a reduction in alkaline phosphatase
(ALP) levels. Seladelpar is the second PPAR agonist
to be approved in the US for this indication; elafibranor
(Iqirvo)...
Med Lett Drugs Ther. 2025 Jan 20;67(1720):13-5 doi:10.58347/tml.2025.1720d | Show Introduction Hide Introduction
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
in the clinical trial were nausea, fatigue, vomiting, alopecia, constipation, decreased appetite, anemia ...
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki
(Enhertu – Daiichi-Sankyo/AstraZeneca), an IV
HER2-directed monoclonal antibody linked to the
topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.
Drugs for Female Sexual Dysfunction
The Medical Letter on Drugs and Therapeutics • Dec 13, 2010 (Issue 1353)
effects of chronic
testosterone use in women include hirsutism, acne,
clitoromegaly, alopecia, lower HDL ...
Sexual complaints related to desire, arousal, orgasm
and painful intercourse are common in women. Since
the last Medical Letter article on this subject, some
new information has become available.
Drugs for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021 (Issue 1620)
–
Ruxience (Pfizer) 7168.00
Mitoxantrone – generic ~60%14 12 mg/m2 IV q3 months Nausea, alopecia, amenorrhea ...
Most patients with multiple sclerosis (MS) present
with the relapsing-remitting form of the disease.
Pharmacologic treatment usually includes a
disease-modifying drug, corticosteroids for acute
exacerbations, and other drugs for managing
symptoms such as fatigue, depression, and pain.
Early use of disease-modifying therapy has improved
clinical outcomes.
Drugs for Acne
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
effects of isotretinoin
include cheilitis, epistaxis, dry skin, alopecia, eczema,
skin fragility ...
Acne is common among adolescents and adults.
Guidelines for treatment of acne were last published
by the American Academy of Dermatology in 2016.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):17-20 doi:10.58347/tml.2024.1695a | Show Introduction Hide Introduction
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
Myelosuppression, opportunistic infections, alopecia,
rash, stomatitis, vomiting, diarrhea, GI hemorrhage ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Chemotherapy for Esophageal, Gastric and Colorectal Cancers
Treatment Guidelines from The Medical Letter • Aug 01, 2006 (Issue 48)
, alopecia, mucositis,
diarrhea, peripheral neuropathy, fatigue and asthenia.
A fluid retention syndrome ...
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
Drugs for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020 (Issue 1600)
targeting
JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia
areata. Dermatol Ther (Heidelb ...
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and has a relapsing course, often improving by
adolescence, but sometimes persisting into (or first
appearing in) adulthood or even old age.
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
occurs frequently with
leflunomide. Reversible alopecia, rash, hypertension,
myelosuppression ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.